Diagnostic Assessment of Platelet Function

Quality in Laboratory Hemostasis and Thrombosis

Volumn , Issue , 2009, Pages 110-124

  Nurden, P ^a   Nurden, A ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

Assessing residual prothrombin (PT) levels; Flow cytometry (FC) and functional status of platelets; GPIb IX V complex binds to multimers of von Willebrand factor (VWF); Platelet aggregometry; Platelet counting with hematology analyzers; Platelet function analysis; Platelet Function Analyzer 100 (PFA 100) closure time (CT) and high shear dependent platelet function; Point of care tests; Proteomics and genomics in studying platelets; Skin bleeding time (BT)

Indexed keywords

EID: 84889624665     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303575.ch12     Document Type: Chapter

References (79)

1. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005; 115: 3348-3354.
2. Andrews, RK, Berndt, MC, Lopez JA. The glycoprotein Ib-IX-V complex. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 145-163.
3. Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn ML. GPVI and a2ß1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood 2005; 106: 1268-1277.
4. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-5095.
5. Balasubramanian Y, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002; 100: 2787-2792.
6. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci 2008; 13: 3532-3548.
7. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004; 3: 913-925.
8. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99: 253-263.
9. Bolton-Maggs PHB, Chalmers EA, Collins PW, Harrison P, Liesner RJ, Minford A, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UK HCDO. Br J Haematol 2006; 13: 603-633.
10. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet lifespan. Cell 2007; 128: 31,173-31,186.
11. Nurden AT, George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In Hemostasis and Thrombosis, 5th edn. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber S, (eds). Philadelphia, PA: Lippincott, Williams & Wilkins, 2006: 987-1010.
12. Gunay-Ayqun M, Huizing M, Gahl WA. Molecular defects that affect platelet dense granules. Semin Thromb Hemost 2004; 30: 537-547.
13. Nurden AT, Nurden P. The Gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007; 21: 21-36.
14. Bussel JB. Immune thrombocytopenic purpura. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 831-846.
15. Aster RH, Bougie DW. Drug-induced thrombocytopenia. New Engl J Med 2007; 357: 580-587.
16. Rao AK. Acquired disorders of platelet function. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 1051-1076.
17. Agah R, Plow EF, Topol EJ. aIIbß3 (GPIIb-IIIa) antagonists. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 1145-1163.
18. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
19. Rodgers RP, Levin J. A critical appraisal of the bleeding time. Semin Thromb Haemost 1990; 16: 1-20.
20. Quick AJ, Favre-Gilly JE. The prothrombin consumption test: Its clinical and theoretic implications. Blood 1949; 4: 1281-1289.
21. Briggs C, Harrison P, Machin SJ. Platelet counting. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 465-483.
22. Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM, et al. Italian Gruppo di Studio delle Piastrine. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 2003; 88: 582-592.
23. Nurden P, George JN, Nurden AT. Inherited thrombocytopenias. In Hemostasis and Thrombosis, 5th edn. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber S, (eds). Philadelphia, PA: Lippincott, Williams & Wilkins, 2006: 975-986.
24. White JG. Platelet structure. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 45-73.
25. Nurden P, Jandrot-Perrus M, Combrié R, Winckler J, Arocas V, Lecut C, et al. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood 2004; 104: 107-114.
26. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: Pro- and anti-angiogenic proteins are organized into separate platelet a-granules and differentially released. Blood 2008; 111: 1227-1233.
27. Harrison P. The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3-10.
28. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. on behalf of the Platelet Physiology Committee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
29. Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98: 4N-10N.
30. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
31. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007; 5: 2393-2398.
32. Steinbuhl SR, Talley JD, Braden GA, Tcheng JE, Castella PJ, Moliterno DJ, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-2578.
33. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, et al. The use of the VerifyNow P2Y12 pointof- care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Hemost 2008; 99: 409-415.
34. Van Werkum JW, Gerritsen WB, Kelder JC, Hackeng CM, Ernst SM, Deneer VH, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomized trial. Neth Heart J 2007; 15: 375-381.
35. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified thromboelastograph and PlateletWorks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145: 309-315.
36. Male C, Koren D, Eichelberger B, Kaufmann K, Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thromboelastography. Vox Sang 2006; 91: 174-177.
37. Diamandis M, Adam F, Kahr WH, Wang P, Chorneyko KA, Arsenault AL, et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analysis of clot lysis. J Thromb Haemost 2006; 4: 1086-1094.
38. Osende JL, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation- based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-1491.
39. Jarvis GE. Platelet aggregation in whole blood: impedence and particle counting methods. Methods Mol Biol 2004; 272: 77-87.
40. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007; 92: 694-697. PLATELET FUNCTION ANALYSIS 123
41. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007; 39: 346-358.
42. Ban B, Dawood A, Wilde JB, Watson SP. Reference curves for aggregation and ATP secretion to aid diagnosis of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A2 pathways. Platelets 2007; 18: 329-345.
43. Cazenave J-P, Ohlmann P, Cassel D, Eckly A, Hechler B, Gachet C. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 2004; 272: 13-28.
44. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279: 4186-4195.
45. Moran N, Kiernan A, Dunne E, Edwards RJ, Shields DC, Kenny D. Monitoring modulators of platelet aggregation in a microtiter plate assay. Anal Biochem 2006; 357: 77-84.
46. Enders A, Zieger B, Schwartz K, Yoshimi A, Speckmann C, Knoepfle C-M, et al. Careful clinical and molecular diagnosis is essential to discriminate between Griscelli syndrome and Hermansky-Pudlak syndrome type II. Blood 2006; 108: 81-87.
47. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, et al. Heterogeneity in storage pool defi- ciency: studies on granule-bound substances in 18 patients including variants deficient in a-granules, platelet factor 4, ß-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296-1319.
48. Michelson AD, Linden MD, Barnard MR, Furman MI, Frelinger AL III. Flow cytometry. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 545-563.
49. Bihour C, Durrieu-Jais C, Macchi L, Poujol C, Coste P, Besse P, et al. Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol 1999; 19: 212-219.
50. Frehlinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MMD, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium and aspirin. Thromb Haemost 2007; 98: 192-200.
51. Linden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007; 4: 761-765.
52. Barnard MR, Linden MD, Frelinger AL 3rd, Li Y, Fox ML, Furman MI, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005; 3: 2563-2570.
53. McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004; 126: 861-869.
54. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular disease. J Thromb Haemost 2005; 3: 85-92.
55. Dachary-Prigent J, Pasquet J-M, Freyssinet J-M, Nurden AT. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+-ATPase inhibitors. Biochemistry 1995; 34: 11,625-11,634.
56. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185-2192.
57. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol 2007; 137: 36-48.
58. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation. Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
59. Milet-Marsal S, Breillat C, Peyruchaud O, Nurden P, Combrie R, Nurden AT, et al. Glanzmann thrombasthenia secondary to a Glu324 to Lys substitution in the aIIb subunit of the fibrinogen receptor: analysis of the amino acid requirement for a normal aIIbß3 maturation. Thromb Haemost 2002; 88: 655-662.
60. Schoenwaelder SM, Yuan Y, Cooray P, Salem HH, Jackson SP. Calpain cleavage of focal adhesion proteins regulates the cytoskeletal attachment of integrin aIIbß3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin clots. J Biol Chem 1997; 272: 1694-1702.
61. Brass LF, Stalker TJ, Zhu L, Woulfe DS. Signal transduction during platelet plug formation. In Platelets, 2nd edn. Michelson A, (ed.). San Diego, CA: Academic Press, 2007: 319-346.
62. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
63. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006; 4: 2317-2326.
64. Pula G, Schuh, K, Nakayama K, Nakayama KI, Walter U, Poole A. PKCd regulates collagen-induced platelet aggregation through inhibition of VASPmediated filopodia formation. Blood 2006; 108: 4035-4044.
65. Thornber K, McCarty, Watson SP, Pears CJ. Distinct but critical roles for integrin aIIbß3 in platelet lamellipodia formation on fibrinogen, collagen-related peptide and thrombin. FEBS Letts 2006; 273: 5032-5043. CHAPTER 12 124
66. McCarty OJT, Calaminus SDJ, Berndt MC, Machesky LM, Watson SP. Von Willebrand factor mediates platelet spreading through glycoprotein Ib and aIIbß3 in the presence of botrocetin and ristocetin, respectively. J Thromb Haemost 2006; 4: 1367-1378.
67. Goto S, Tamura N, Arai M, Kodama R, Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002; 106: 266-272.
68. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006; 107: 3537-3545.
69. Nesbitt WS, Giuliano S, Kulkarni S, Dopheide SM, Harper IS, Jackson, SP. Intracellular calcium communication regulates platelet aggregation and thrombus growth. J Cell Biol 2003; 160: 1151-1161.
70. Garcia A, Prabhakar S, Brock CJ, Pearce AC, Dwek RA, Watson SP, et al. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004; 4: 656-668.
71. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB. Moderation of the platelet release response by aspirin. Blood 2007; 109: 4786-4792.
72. Maguire PB, Wynne KJ, Harney DF, O'Donoghue NM, Stephens G, Fitzgerald DJ. Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics 2002; 2: 642-648.
73. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-2293.
74. Bugert P, Dugrillon A, Günaydin A, Eichler H, Klüter H. Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost 2003; 90: 738-748.
75. Sun L, Gorospe JR, Hoffman EP, Rao AK. Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost 2007; 5: 146-154.
76. Jones CI, Garner SF, Angenent W, Bernard A, Berzuini C, Burns P, et al. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. J Thromb Haemost 2007; 5: 1756-1765.
77. Nelson EJ, Nair SC, Peretz H, Coller BS, Seligsohn U, Chandy M, et al. Diversity of Glanzmann thrombasthenia in Southern India: 10 novel mutations identified among 15 unrelated patients. J Thromb Haemost 2006; 4: 1730-1737.
78. Castro V, Kroll H, Origa AF, Falconi MA, Marques SBD, Marba ST, et al. A prospective study on the prevalence and risk factors for neonatal thrombocytopenia among unselected Brazilian newborns. Transfusion 2007; 47: 59-66.
79. Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001; 98: 85-92.